Recombinant Human Aminopeptidase N/CD13 His Avi Protein, CF New
Recombinant Human Aminopeptidase N/CD13 His Avi Protein, CF Summary
Product Specifications
Human APN (Lys69-Lys967) Accession # AAA51719.1 | 6-His tag | Avi-tag |
N-terminus | C-terminus | |
Analysis
Biotinylated via Avi-tag
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
AVI3815
Formulation | Supplied as a 0.2 μm filtered solution in MES and NaCl. |
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 50 mM Tris, 0.05%(w/v) Brij 35, pH 7.0
- Biotinylated Recombinant Human Aminopeptidase N/CD13 His-tag Avi-tag (rhAPN/His/Avitag) (Catalog # AVI3815)
- Substrate: Ala-AMC, 10 mM stock in DMSO
- Black 96-well Plate
- Plate Reader with Fluorescence Read Capability
- Dilute rhAPN/His/Avitag to 0.2 µg/mL in Assay Buffer.
- Dilute Substrate to 400 µM in Assay Buffer.
- Load into a plate 50 µL of 0.2 µg/mL rhAPN/His/Avitag, and start the reaction by adding 50 µL of 400 µM Substrate. Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of 400 µM Substrate.
- Read at excitation and emission wavelengths of 380 nm and 460 nm (top read), respectively in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = | Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) |
amount of enzyme (µg) |
- rhAPN/His/Avitag: 0.01 µg
- Substrate: 200 µM
Scientific Data
Biotinylated Recombinant Human Aminopeptidase N/CD13 His-tag Avi-tag Protein (Catalog # AVI3815) binds Human Aminopeptidase N/CD13 Antibody (AF3815) with an ED50 of 1.80-18.0 ng/mL.
Biotinylated Recombinant Human Aminopeptidase N/CD13 His-tag Avi-tag Protein (Catalog # AVI3815) is measured by its ability to cleave the fluorogenic peptide substrate, Ala-7-amido-4-methylcoumarin (Ala-AMC).
2 μg/lane of Biotinylated Recombinant Human Aminopeptidase N/CD13 His-tag Avi-tag Protein (Catalog # AVI3815) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 116-130 kDa, under reducing conditions.
Reconstitution Calculator
Background: Aminopeptidase N/CD13
Aminopeptidase N (APN) is a type II transmembrane zinc-dependent metalloprotease that is widely expressed in many cells, tissues, and species. APN forms an active homodimer where each monomer contains a short cytoplasmic tail, a transmembrane region, and an extracellular domain with a Ser/Thr rich region and a metalloprotease catalytic domain (1,2). APN is also known as leukocyte surface differentiation antigen CD13, microsomal aminopeptidase, alanyl aminopeptidase, and aminopeptidase M (1-3). The protein cleaves the N-terminal neutral amino acids from bioactive peptides like neuropeptides and immunomodulatory peptides including oxytocin, vasopressin, angiotensin III, and tuftsin resulting in their degradation or modulation (2,4). Consequently, APN is implicated to play many biological roles within the immune system, angiogenesis, mestastasis, and cancer (2). Both APN expression and activity are altered in cancer making it a marker and a pharmacological intervention target (5,6). It is targeted in CAR T therapies for cancers such as B-cell lymphoma and multiple myeloma (2,7). In addition, APN serves as a receptor for several human viruses such as coronavirus 229E (8) and human cytomegalovirus making it of interest as a target in these fields (9,10).
- Look, A.T. et al. (1989) J. Clin. Invest. 83:1299.
- Lendeckel, U. et al. (2023) Biomedicines. 11:724.
- Olsen, J. et al. (1988) FEBS Lett. 238:307.
- Hansen, A.S. et al. (1993) Eur. J. Immunol. 23:2358.
- Li, H. et. al. (2019) Chem. Sci. 10:1619
- Shimizu, T. et. al. (2024) Front. Surg. 11:1298709.
- He, X. et. al. (2020) Blood 135:713.
- Yeager, C.L. et. al. (1992) Nature 357:420.
- Soderberg, C. et. al. (1993) J. Virol. 67: 6576
- Fu, Z. et. al. (2024) J. Virol. 98:e0123923.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Aminopeptidase N/CD13 His Avi Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Aminopeptidase N/CD13 His Avi Protein, CF and earn rewards!
Have you used Recombinant Human Aminopeptidase N/CD13 His Avi Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image